Bajaj Healthcare secures NCLT approval for Genrx acquisition
- NCLT Mumbai Bench approved the acquisition on October 13, 2026
- Genrx Pharmaceuticals to become a wholly owned subsidiary
- Trading window remains closed for designated persons
*this image is generated using AI for illustrative purposes only.
Bajaj Healthcare Limited received approval from the National Company Law Tribunal (NCLT) Mumbai Bench for the acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis.
The order was passed on October 13, 2026, and downloaded by the company on the same day. This development follows earlier disclosures made in April 2025 regarding the proposed acquisition of the entity, which is currently in liquidation.
Acquisition Details and Structure
Under the terms approved by the NCLT, Genrx Pharmaceuticals Private Limited will become a wholly owned subsidiary of Bajaj Healthcare Limited. The acquisition is subject to the implementation of specific terms outlined in the tribunal's order.
The NCLT order remains effective from October 13, 2026, until any further orders or directions are issued by the tribunal. The company stated it will take necessary actions in accordance with these terms.
Regulatory Compliance and Trading Window
Bajaj Healthcare disclosed this information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no aberrations or non-compliances were identified by the authority in the communication.
Furthermore, the trading window for dealing in securities of Bajaj Healthcare Limited remains closed for all designated persons and their immediate relatives. This restriction continues in line with the company's code of internal procedures and earlier disclosures dated September 23, 2026.
Key Disclosure Points
| Particulars | Details |
|---|---|
| Authority | Hon'ble National Company Law Tribunal, Mumbai Bench |
| Order Date | October 13, 2026 |
| Target Entity | Genrx Pharmaceuticals Private Limited (in Liquidation) |
| Outcome | Approved on a going concern basis |
| Subsidiary Status | Wholly owned subsidiary of Bajaj Healthcare Limited |
| Penalty/Sanction | Not Applicable |
Historical Stock Returns for Bajaj HealthCare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.85% | +2.55% | -0.81% | -1.00% | -27.62% | -8.71% |
What specific therapeutic segments or product lines will Bajaj Healthcare gain access to through the acquisition of Genrx Pharmaceuticals?
How does the 'going concern' status impact the immediate operational integration costs and timeline for Bajaj Healthcare?
Will the acquisition of Genrx Pharmaceuticals significantly alter Bajaj Healthcare's consolidated revenue guidance for the upcoming fiscal year?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
